報價延遲最少15分鐘:2026/04/16 13:20 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.45 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.11/-1.53
|
|
企業價值
282.64M
|
| 資產負債 |
|
每股賬面淨值
0.92
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
33.48M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. Ithas one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies. |
